Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 5 , Pages 653-658 , May 2007

Pharmacotherapy of Aggression in a 9-Year-Old With ADHD

,Accepted 8 December 2006.

REFERENCES 

  1. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15:869–884
  2. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243–254
  3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601
  4. Bassarath L. Medication strategies in childhood aggression: a review. Can J Psychiatry. 2003;48:367–373
  5. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1995;34:445–453
  6. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14:372–394
  7. Connor DF, Carlson GA, Chang KD, et al. Juvenile maladaptive aggression: a review of prevention, treatment, and service configuration and a proposed research agenda. J Clin Psychiatry. 2006;67:808–820
  8. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:253–261
  9. Findling R, Blumer J, Kauffman R, et al. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. Int J Neuropsychopharmacol. 2004;7:S440
  10. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:792–800
  11. Greene RW, Ablon JS. Treating Explosive Kids: The Collaborative Problem-Solving Approach. New York: Guilford; 2005;
  12. Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35:1304–1313
  13. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S–49S
  14. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42:886–894
  15. Malone RP, Delaney MA. Psychopharmacologic interventions in children with aggression: neuroleptics, lithium, and anticonvulsants.. In:  Coccaro EF editors. Aggression: Assessment and Treatment. New York: Marcel Dekker; 2003;
  16. MTA Cooperative Group . Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry. 1999;56:1088–1096
  17. MTA Cooperative Group . National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762–769
  18. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:240–248
  19. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16:379–392
  20. Pappadopulos E, MacIntyre JC, Crismon ML, et al. Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). II: Recommendations for clinicians. J Am Acad Child Adolesc Psychiatry. 2003;42:145–161
  21. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642–657
  22. Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am. 2006;15:13–50
  23. Schur SB, Sikich L, Findling RL, et al. Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). I: a review. J Am Acad Child Adolesc Psychiatry. 2003;42:132–144
  24. Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther. 2006;28:402–418

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacologic management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Findling receives or has received research support from, acted as a consultant to, or served on a speakers' bureau of Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka, Pfizer, Shire, Sanofi-Aventis, Solvay, and Wyeth. Dr. Malone has received investigator-initiated funding from Eli Lilly, Pfizer, and Bristol-Myers Squibb and served as a consultant to Eli Lilly. Dr. Prince is a member of the speakers' bureaus of McNeil and Janssen; has received honoraria from Shire, Novartis, and Cephalon; and has been a consultant to Shire, Novartis, Cephalon, and McNeil. Dr. Kratochvil has received grant support from, is a consultant to, and/or member of the speakers' bureaus of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Newcorn receives research support from McNeil Pediatrics and Eli Lilly and is a consultant to, advisor to, or speaker for McNeil Pediatrics, Shire, Novartis, Eli Lilly, Cephalon, Cortex, and Pfizer. Dr. Waheed has no financial relationships to disclose.

PII: S0890-8567(09)61725-1

doi: 10.1097/chi.0b013e3180335b4a

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 5 , Pages 653-658 , May 2007

Article Tools